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Mechanism for the synergistic effect of rapamycin and resveratrol on
hyperinsulinemia may involve the activation of protein kinase B
Abstract

Dear Editor, We read with great interest Leontiev et al.'s paper entitled 'Resveratrol potentiates rapamycin to
prevent hyperinsulinemia and obesity in male mice on high-fat diet' recently published in Cell Death &
Disease.1 Their finding that rapamycin and resveratrol have a synergistic effect is important for treating insulin
resistance. They showed that rapamycin inhibited mammalian target of rapamycin (mTOR) activity, while
resveratrol inhibited S6 kinase (S6K). We think that these compounds may exert their effects through
activating protein kinase B (Akt), a key regulator of insulin sensitivity. Both the inhibition of mTOR by
rapamycin and of S6K by resveratrol could result in the activation of Akt due to the release of feedback
inhibition on the insulin receptor substrates (IRS), which are stimulators of Akt.
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Dear Editor,
We read with great interest Leontiev et al.’s paper
entitled ‘Resveratrol potentiates rapamycin to prevent
hyperinsulinemia and obesity in male mice on high-fat
diet’ recently published in Cell Death & Disease.1 Their
finding that rapamycin and resveratrol have a synergistic
effect is important for treating insulin resistance. They
showed that rapamycin inhibited mammalian target of
rapamycin (mTOR) activity, while resveratrol inhibited S6
kinase (S6K). We think that these compounds may exert
their effects through activating protein kinase B (Akt), a key
regulator of insulin sensitivity. Both the inhibition of mTOR
by rapamycin and of S6K by resveratrol could result in the
activation of Akt due to the release of feedback inhibition
on the insulin receptor substrates (IRS), which are stimulators of Akt.
Insulin resistance is a pathophysiological condition often
occurring in diabetes, metabolic syndrome and obesity. As
there is a high incidence of diabetes and obesity, there is also
insulin resistance in a large proportion of the population. In
insulin resistance, adipocytes and muscle cells are no longer
sensitive to insulin and thus their uptake of glucose is
reduced.2 Hepatic cells also fail to convert glucose into
glycogen. As a result, blood glucose levels are increased,
and insulin secretion is correspondingly increased, causing
hyperinsulemia. It has been recognized that hyperinsulinemia
is associated with many co-morbidities such as cancer
and heart disease. Insulin can activate several intracellular
signal pathways—including phosphoinositide 3-kinase
(PI3K)/Akt and mitogen-activated protein kinase (MAPK)—to
increase cell proliferation and decrease apoptosis, thus
facilitating carcinogenesis and leading to poorer prognosis
to cancer therapy.3 Therefore, it is important to control
hyperinsulinemia.
Akt has been demonstrated to be a key regulator in
the insulin-induced transportation of glucose into cells.
The downstream target protein AS160 can increase the
translocation of glucose transporter 4 (Glut 4) from intracellular vesicles to the plasma membrane.4 In mice, an Akt

knockdown is sufficient to cause a diabetic phenotype.5
In humans, the loss of Akt function due to a mutation is
associated with diabetes.6 In Leontiev et al.’s paper, it is
shown that rapamycin and resveratrol have a synergistic
effect in lowering hyperinsulinemia.1 The authors explored the
effect of rapamycin and resveratrol on two components of the
PI3K/Akt pathway, mTOR and S6K. However, their effects on
the levels of phosphorylated Akt (pAkt) were not examined.
We think that rapamycin and resveratrol may synergistically
activate Akt to increase insulin sensitivity in mice fed with a
high-fat diet.
The insulin/PI3K/Akt signaling is negatively regulated by a
feedback loop acting on Akt.3 In this pathway, insulin activates
the insulin receptor that phosphorylates IRS, leading to the
activation of the PI3K/Akt pathway. One of the Akt target
proteins is mTOR, which regulates S6K. The S6K negatively
regulates IRS, leading to the inhibition of the Akt activity.3 In
Leontieva et al.’s study, rapamycin was shown to inhibit
mTOR, which should lead to decreased phosphorylated S6K
(pS6K), and subsequently result in the activation of Akt
(Supplementary Figure 1).
Resveratrol can inhibit pS6K directly as shown in
Leontieva et al.’s study. It could also cause the activation
of Akt (Supplementary Figure 1), which was not examined in
the study. Nevertheless, another study has shown that
resveratrol does increase pAkt in muscle cells in type
2 diabetes.7 Inhibition of AMP-activated protein kinase
by resveratrol in muscle cells may also contribute to
an increase in pAkt.8 The combinatorial application of
rapamycin and resveratrol may result in a stronger inhibition
of pS6K, and thus a higher activation of pAkt. This may
explain the synergistic effect of the two compounds used
in this study.
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